RGD Reference Report - Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine.

Authors: Voso, M T  Fabiani, E  Piciocchi, A  Matteucci, C  Brandimarte, L  Finelli, C  Pogliani, E  Angelucci, E  Fioritoni, G  Musto, P  Greco, M  Criscuolo, M  Fianchi, L  Vignetti, M  Santini, V  Hohaus, S  Mecucci, C  Leone, G 
Citation: Voso MT, etal., Leukemia. 2011 Dec;25(12):1910-3. doi: 10.1038/leu.2011.170. Epub 2011 Jul 15.
RGD ID: 14392809
Pubmed: PMID:21760590   (View Abstract at PubMed)
DOI: DOI:10.1038/leu.2011.170   (Journal Full-text)

Abstract for this paper unavailable

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
myelodysplastic syndrome treatmentIDA 14392809 RGD 
myelodysplastic syndrome treatmentISOBCL2L10 (Homo sapiens)14392809; 14392809 RGD 

Objects Annotated

Genes (Rattus norvegicus)
Bcl2l10  (Bcl2-like 10)

Genes (Mus musculus)
Bcl2l10  (Bcl2-like 10)

Genes (Homo sapiens)
BCL2L10  (BCL2 like 10)


Additional Information